{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T12:55:31Z","timestamp":1792155331116,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.urolonc.2012.04.010","type":"journal-article","created":{"date-parts":[[2012,7,3]],"date-time":"2012-07-03T12:01:56Z","timestamp":1341316916000},"page":"1635-1642","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":129,"title":["Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu\u00e9rin"],"prefix":"10.1016","volume":"31","author":[{"given":"Colin P.N.","family":"Dinney","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard E.","family":"Greenberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary D.","family":"Steinberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6 Suppl 1","key":"10.1016\/j.urolonc.2012.04.010_bib1","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1016\/j.urology.2005.07.062","article-title":"Bladder cancer: Epidemiology, staging and grading, and diagnosis","volume":"66","author":"Kirkali","year":"2005","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2012.04.010_bib2","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1016\/j.juro.2011.07.076","article-title":"A review of current guidelines and best practice recommendations for the management of nonmuscle invasive bladder cancer by the international bladder cancer group","volume":"186","author":"Brausi","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib3","series-title":"NCCN clinical practice guidelines in oncology (NCCN guidelines): Bladder cancer, version 2.2011","author":"Montie","year":"2011"},{"key":"10.1016\/j.urolonc.2012.04.010_bib4","doi-asserted-by":"crossref","first-page":"2314","DOI":"10.1016\/j.juro.2007.09.003","article-title":"Guideline for the management of nonmuscle invasive bladder cancer (stages Ta, T1, and Tis): 2007 update","volume":"178","author":"Hall","year":"2007","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib5","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1016\/j.eururo.2011.03.017","article-title":"EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder, the 2011 update","volume":"59","author":"Babjuk","year":"2011","journal-title":"Eur Urol"},{"issue":"Suppl","key":"10.1016\/j.urolonc.2012.04.010_bib6","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.eursup.2008.07.007","article-title":"Current approaches to the management of non-muscle-invasive bladder cancer: Comparison of current guidelines and recommendations","volume":"7","author":"Persad","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib7","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2009.11.023","article-title":"The role of bacillus Calmette-Guerin in the treatment of non-muscle-invasive bladder cancer","volume":"57","author":"Gontero","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib8","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ctrv.2009.12.005","article-title":"Intravesical therapy for superficial bladder cancer: A systematic review of randomised trials and meta-analyses","volume":"36","author":"Shelley","year":"2010","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.urolonc.2012.04.010_bib9","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1097\/01.ju.0000162059.64886.1c","article-title":"Bacillus CalmetteGuerin versus chemotherapy for the intravesical treatment of patients with carcinoma in situ of the bladder: A meta-analysis of the published results of randomized clinical trials","volume":"174","author":"Sylvester","year":"2005","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib10","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1016\/j.urology.2005.12.014","article-title":"Can intravesical bacillus Calmette-Guerin reduce recurrence in patients with superficial bladder cancer?","volume":"67","author":"Han","year":"2006","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2012.04.010_bib11","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1111\/j.1442-2042.2010.02678.x","article-title":"Bacillus Calmette-Guerin treatment of non-muscle-invasive bladder cancer","volume":"18","author":"Sylvester","year":"2011","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib12","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1111\/j.1464-410X.2010.09272.x","article-title":"Failure of bacille Calmette-Guerin in patients with high risk non-muscle-invasive bladder cancer unsuitable for radical cystectomy: An update of available treatment options","volume":"106","author":"Yates","year":"2010","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2012.04.010_bib13","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.urolonc.2007.11.033","article-title":"Failure to achieve a complete response to induction BCG therapy is associated with increased risk of disease worsening and death in patients with high risk non-muscle-invasive bladder cancer","volume":"27","author":"Lerner","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib14","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/S0302-2838(02)00491-8","article-title":"Beware the BCG failures: A review of one institution's results","volume":"42","author":"Lockyer","year":"2002","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib15","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1111\/j.1464-410X.2008.07889.x","article-title":"Risk factors for mortality and morbidity related to radical cystectomy","volume":"103","author":"Bostrom","year":"2009","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2012.04.010_bib16","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1016\/j.eururo.2007.12.031","article-title":"Outcome of patients who refuse cystectomy after receiving neoadjuvant chemotherapy for muscle-invasive bladder cancer","volume":"54","author":"Herr","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib17","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1586\/era.10.155","article-title":"Developments in intravesical therapy for non-muscle-invasive bladder cancer","volume":"10","author":"Lammers","year":"2010","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.urolonc.2012.04.010_bib18","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1016\/j.juro.2008.11.019","article-title":"Intravesical mycobacterial cell wall-DNA complex in the treatment of carcinoma in situ of the bladder after standard intravesical therapy has failed","volume":"181","author":"Morales","year":"2009","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib19","series-title":"Valstar\u00ae [package insert]","year":"2011"},{"key":"10.1016\/j.urolonc.2012.04.010_bib20","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/978-3-642-81565-2_2","article-title":"Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32","volume":"76","author":"Blum","year":"1981","journal-title":"Recent Results Cancer Res"},{"key":"10.1016\/j.urolonc.2012.04.010_bib21","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/S0090-4295(96)00621-8","article-title":"Initial report on intravesical administration of N-trifluoroacetyladriamycin-14-valerate (AD 32) to patients with refractory superficial transitional cell carcinoma of the urinary bladder","volume":"49","author":"Greenberg","year":"1997","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2012.04.010_bib22","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.urolonc.2008.05.004","article-title":"Phase II study of intravesical therapy with AD32 in patients with papillary urothelial carcinoma or carcinoma in situ (CIS) refractory to prior therapy with bacillus Calmette-Guerin (E3897): A trial of the Eastern Cooperative Oncology Group","volume":"27","author":"Ignatoff","year":"2009","journal-title":"Urol Oncol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib23","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1016\/S0090-4295(00)00654-3","article-title":"Pilot study of the tolerability and toxicity of intravesical valrubicin immediately after transurethral resection of superficial bladder cancer","volume":"56","author":"Patterson","year":"2000","journal-title":"Urology"},{"key":"10.1016\/j.urolonc.2012.04.010_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0022-5347(05)67799-3","article-title":"Efficacy and safety of valrubicin for the treatment of bacillus Calmette-Guerin refractory carcinoma in situ of the bladder","volume":"163","author":"Steinberg","year":"2000","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib25","doi-asserted-by":"crossref","first-page":"28","DOI":"10.3810\/pgm.2011.05.2281","article-title":"Factors affecting valrubicin response in patients with bacillus Calmette-Guerin refractory bladder carcinoma in situ","volume":"123","author":"Steinberg","year":"2011","journal-title":"Postgrad Med"},{"key":"10.1016\/j.urolonc.2012.04.010_bib26","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/715892","article-title":"Health-related quality of life after cystectomy and urinary diversion for bladder cancer","volume":"2011","author":"Shih","year":"2011","journal-title":"Adv Urol"},{"key":"10.1016\/j.urolonc.2012.04.010_bib27","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1016\/j.urology.2010.07.537","article-title":"Perioperative mortality is significantly greater in septuagenarian and octogenarian patients treated with radical cystectomy for urothelial carcinoma of the bladder","volume":"77","author":"Liberman","year":"2011","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.urolonc.2012.04.010_bib28","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.urology.2010.02.053","article-title":"Age and body mass index are independent risk factors for the development of postoperative paralytic ileus after radical cystectomy","volume":"76","author":"Svatek","year":"2010","journal-title":"Urology"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143912001512?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143912001512?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:03:13Z","timestamp":1761040993000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143912001512"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":28,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S1078143912001512"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.04.010","relation":{},"ISSN":["1078-1439"],"issn-type":[{"value":"1078-1439","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravesical valrubicin in patients with bladder carcinoma in situ and contraindication to or failure after bacillus Calmette-Gu\u00e9rin","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2012.04.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}